P&G signals its intent with Merck acquisition
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Procter & Gamble (P&G) is set to acquire for €3.4 billion Merck KGaA’s Consumer Health business, in a move the consumer- goods giant claims will improve significantly its “geographic scale, brand portfolio and category footprint” in the world’s leading OTC markets. Subject to regulatory approvals, the transaction is expected to close by the end of the fourth quarter.
You may also be interested in...
P&G Introduces Nervive ‘Nerve Relief’ Supplements In US, Extending Line Acquired From Merck
P&G launches Nervive three-product line for nerve discomfort inspired by 50-year-old Neurobion brand marketed in Europe, Asia and Latin America. The products contain B-complex vitamins and alpha lipoic acid to promote blood flow.
P&G Given Green Light To Offload Haliborange Supplements
P&G's decision to offload its Haliborange children's supplement line will not lead to reduced competition in the UK market, according to the regulator.
P&G Raises Guidance On Strong Q1 With Analysts Anticipating Headwinds
Net and organic sales up 7% to $17.8bn in its FY 2020 Q1 as its turnaround takes hold and pricing increases it implemented a year ago push revenues. CFO Jon Moeller says P&G revises guidance upwards for FY2020 and is better positioned to counter potential recession headwinds than it was in 2008.